Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Teva, Biogen, Ionis, Sage And The Art Of Strategic News Placement

Executive Summary

Earnings announcements from Teva and clinical trial results from Biogen, Ionis and Sage have turned out to have quite different interpretations in retrospect. Exciting news can sometimes look more like a vehicle for strategically timed stock promotion than a genuine material event.

You may also be interested in...



Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question

Biogen's share price has risen on speculation that it is an acquisition target for Merck & Co and Allergan. But with a number of uncertainties hanging over the company, can Biogen negotiate a premium price?

Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.

Teva’s Rosy View For A Happy Union With Allergan Generics

The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel